Integra LifeSciences Holdings Corp. (NASDAQ:IART) announced its earnings results on Monday. The company reported $0.72 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.70 by $0.02, AnalystRatings.Net reports. The company had revenue of $213.20 million for the quarter, compared to the consensus estimate of $214.05 million. During the same quarter in the prior year, the company posted $0.85 earnings per share. The company’s quarterly revenue was up 1.5% on a year-over-year basis. Integra LifeSciences Holdings Corp. updated its FY13 guidance to $2.50-$2.60 EPS.
Several analysts have recently commented on the stock. Analysts at Morgan Stanley downgraded shares of Integra LifeSciences Holdings Corp. from an “equal weight” rating to an “underweight” rating in a research note to investors on Wednesday, October 23rd. They now have a $40.00 price target on the stock. On a related note, analysts at Barclays initiated coverage on shares of Integra LifeSciences Holdings Corp. in a research note to investors on Friday, October 4th. They set an “equal weight” rating and a $43.00 price target on the stock. Finally, analysts at Jefferies Group raised their price target on shares of Integra LifeSciences Holdings Corp. from $43.00 to $46.00 in a research note to investors on Thursday, August 22nd. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $42.62.
Shares of Integra LifeSciences Holdings Corp. (NASDAQ:IART) traded up 0.53% on Monday, hitting $43.65. The stock had a trading volume of 213,417 shares. Integra LifeSciences Holdings Corp. has a 52-week low of $30.87 and a 52-week high of $44.53. The stock has a 50-day moving average of $39.95 and a 200-day moving average of $37.88. The company has a market cap of $1.226 billion and a price-to-earnings ratio of 48.19.
Integra LifeSciences Holdings Corporation (NASDAQ:IART) is an integrated medical technology company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.